Current Opinion in the Role of Testosterone in the Development of Prostate Cancer: A Dynamic Model by Xu, Xiaohui et al.
Health Sciences Faculty Publications Health Sciences
10-2015
Current Opinion in the Role of Testosterone in the
Development of Prostate Cancer: A Dynamic
Model
Xiaohui Xu





See next page for additional authors
Follow this and additional works at: https://cupola.gettysburg.edu/healthfac
Part of the Male Urogenital Diseases Commons, Oncology Commons, and the Other Medicine
and Health Sciences Commons
Share feedback about the accessibility of this item.
This is the publisher's version of the work. This publication appears in Gettysburg College's institutional repository by permission of
the copyright owner for personal use, not for redistribution. Cupola permanent link: https://cupola.gettysburg.edu/healthfac/70
This open access article is brought to you by The Cupola: Scholarship at Gettysburg College. It has been accepted for inclusion by an
authorized administrator of The Cupola. For more information, please contact cupola@gettysburg.edu.
Xu, Xiaohui, Xinguang Chen, Hui Hu, Amy B. Dailey, and Brandie D.Taylor. "Current Opinion in the Role of Testosterone in the
Development of Prostate Cancer: A Dynamic Model." BMC Cancer 15.806 (October 2015), 1-8.
Current Opinion in the Role of Testosterone in the Development of
Prostate Cancer: A Dynamic Model
Abstract
Background: Since the landmark study conducted by Huggins and Hodges in 1941, a failure to distinguish
between the role of testosterone in prostate cancer development and progression has led to the prevailing
opinion that high levels of testosterone increase the risk of prostate cancer. To date, this claim remains
unproven.
Presentation of the Hypothesis: We present a novel dynamic mode of the relationship between testosterone
and prostate cancer by hypothesizing that the magnitude of age-related declines in testosterone, rather than a
static level of testosterone measured at a single point, may trigger and promote the development of prostate
cancer.
Testing of the Hypothesis: Although not easily testable currently, prospective cohort studies with
population-representative samples and repeated measurements of testosterone or retrospective cohorts with
stored blood samples from different ages are warranted in future to test the hypothesis.
Implications of the Hypothesis: Our dynamic model can satisfactorily explain the observed age patterns of
prostate cancer incidence, the apparent conflicts in epidemiological findings on testosterone and risk of
prostate cancer, racial disparities in prostate cancer incidence, risk factors associated with prostate cancer, and
the role of testosterone in prostate cancer progression. Our dynamic model may also have implications for
testosterone replacement therapy.
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Current opinion on the role of testosterone
in the development of prostate cancer: a
dynamic model
Xiaohui Xu1*, Xinguang Chen2, Hui Hu2, Amy B. Dailey3 and Brandie D. Taylor1
Abstract
Background: Since the landmark study conducted by Huggins and Hodges in 1941, a failure to distinguish
between the role of testosterone in prostate cancer development and progression has led to the prevailing opinion
that high levels of testosterone increase the risk of prostate cancer. To date, this claim remains unproven.
Presentation of the hypothesis: We present a novel dynamic mode of the relationship between testosterone and
prostate cancer by hypothesizing that the magnitude of age-related declines in testosterone, rather than a static
level of testosterone measured at a single point, may trigger and promote the development of prostate cancer.
Testing the hypothesis: Although not easily testable currently, prospective cohort studies with population-
representative samples and repeated measurements of testosterone or retrospective cohorts with stored blood
samples from different ages are warranted in future to test the hypothesis.
Implications of the hypothesis: Our dynamic model can satisfactorily explain the observed age patterns of
prostate cancer incidence, the apparent conflicts in epidemiological findings on testosterone and risk of prostate
cancer, racial disparities in prostate cancer incidence, risk factors associated with prostate cancer, and the role of
testosterone in prostate cancer progression. Our dynamic model may also have implications for testosterone
replacement therapy.
Keywords: Prostate Cancer, Testosterone, Androgen, Dynamic model
Background
Prostate cancer (PCa) is the most common cancer and
the second leading cause of cancer mortality among
American men. In 2014, approximately 233,000 men
were diagnosed with PCa and 29,480 PCa-related deaths
were reported [1]. Despite high incidence and mortality
rates of PCa, the biological mechanism related to the de-
velopment and progression of PCa remains largely un-
known. The prostate is an androgen-regulated organ and
there is a long-standing interest in understanding the
role of androgens in the development of PCa [2, 3]. An-
drogens are a class of sex steroid hormones which in
males, stimulate and control the development and main-
tenance of male characteristics including growth and
function of the prostate. Testosterone and its derivative,
dihydrotestosterone (DHT), are the two most abundant
androgens in males. Approximately 90 % of testosterone
is produced by Leydig cells in the testes and an add-
itional 10 % is produced by adrenal glands [4]. DHT is
the primary effector androgen and is converted from tes-
tosterone by 5α-Reductase [4]. DHT becomes biologic-
ally active by forming the androgen-receptor complex,
which is then translocated from the cytoplasm into the
cell nucleus to modulate gene expression [5].
The landmark study by Huggins and Hodges in 1941
suggested a direct correlation between circulating levels
of testosterone and PCa progression [6]. It was the first
study to show that both progression and regression of
PCa are testosterone-dependent. These findings led to
the prevailing hypothesis that elevated androgen levels
increase the risk of PCa. However, Huggins and Hodge’s
study only provided evidence on the role of testosterone
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in the progression of PCa. Therefore, this widely accepted
opinion fails to distinguish the role of testosterone in PCa
development. Despite more than 70 years passing since
the study was conducted, little progress has been made in
understanding the role of testosterone in the development
of PCa. Furthermore, evidence from epidemiological stud-
ies remains controversial. Some studies supported the pre-
vailing opinion that high testosterone levels are associated
with an increased risk of PCa [7–11] while others have
found negative associations between testosterone and risk
of PCa [12–15] or no association [16–24]. A pooled ana-
lysis of 19 published studies by Roddam et al. (2008)
found no statistically significant association between
testosterone and the risk of PCa [25].
All of these studies were guided by a static paradigm,
which investigated the relationship between testosterone
and PCa at a single point in cases and controls. Al-
though this type of study design is often more feasible, it
is not able to examine the relationship between the
change of testosterone with age and PCa risk. Further-
more, these studies did not analyze the role of testoster-
one in the development of PCa in the context of
individual variation of testosterone level and are insuffi-
cient to examine the complex etiological role of testos-
terone in the carcinogenesis process of PCa. New
paradigms are needed to further understand the current
data and to guide us to advance PCa research in the
future.
Based on evidence from published studies, we propose
a dynamic model as a theoretical framework to under-
stand the relationship between testosterone and the de-
velopment of PCa. As an illustration, we propose a
dynamic model to interpret and improve our under-
standing of the following: the observed age patterns of
PCa, the inconsistent findings from published studies,
the racial disparities in PCa incidence, the risk and pro-
tective factors for PCa, the role of testosterone in PCa
growth and the use of androgen replacement therapy as
primary prevention of PCa.
Presentation of the hypothesis
Two key components are included in our dynamic model:
the magnitude of the age-related declines in testosterone
and the individual-based threshold level of testosterone to
maintain the normal function of prostate gland. Our
model emphasizes that the absolute value of testosterone
measured at a single point is not indicative of PCa risk. In-
stead, the magnitude of the age-related declines in testos-
terone is a key factor. The risk of PCa increases when
testosterone levels fall below a threshold. As testosterone
level falls below the threshold, prostatic cells reach the
limit of their compensatory capabilities, thus impairing
adaption to lower levels of testosterone and finally trigger-
ing the prostatic carcinogenesis process (See Fig. 1).
Testing the hypothesis
The hypothesis can be tested with prospective cohort
studies with longitudinal monitoring testosterone levels in
males or retrospective cohort studies with testosterone
data available at different ages or stored blood samples
collected at different ages available for testing testoster-
one. With the study design and data, we are able to make
a comparison of the patterns of testosterone change over
time between cases and controls. For the threshold level,
the absolute or relative differences of testosterone levels
between young adulthood and at the time of prostate can-
cer diagnosis may provide important insights about it. In
addition, the relative differences of testosterone levels be-
tween young adulthood and old age (e.g. 65 years old)
may also provide some clues about the threshold level as
most of prostate cancer occurs in old age.
Implications of the hypothesis
The dynamic model and the effect of age on PCa
After the age of 50, the incidence of PCa increases expo-
nentially with age [26, 27]. Prior studies have yielded
rich data regarding the age patterns of testosterone. Tes-
tosterone levels are increased in pubertal adolescence,
then peak between 30-40 years, and subsequently falling
thereafter at the rate of 2–3 % per year [28–30]. In some
men, normal prostate cells develop into tumor cells with
age after testosterone level reaches blow a certain level
(i.e. individual-based threshold), leading to PCa. Figure 1
illustrates the parallels of PCa development and declin-
ing testosterone levels. Studies of age patterns of testos-
terone levels suggest that only a small proportion of
individuals have testosterone levels below the threshold
before age 50. Consequently, PCa risk is very low among
this young population. However, after age 50, the pro-
portion of individuals with testosterone levels below the
threshold increases dramatically with each. As a result,
PCa risk also increases exponentially.
The dynamic model and the role of testosterone in the
development of PCa
Previous research studies have been limited by static
models examining the relationship between testosterone
levels and PCa. Most published epidemiological studies
measured testosterone at a single point in time, which
may contribute to the inconsistent findings in the field.
Our dynamic model may help explain conflicting find-
ings. For example, in a group of individuals with PCa who
had higher levels of testosterone than others when they
were young, their testosterone levels are relatively higher
at the time of cancer diagnosis, although they may already
have experienced significant declines in testosterone. If
such patients are included in research, high testosterone
level will be detected as a risk factor for PCa when com-
pared with controls who have relatively lower peak
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testosterone at young age (See Fig. 2-Scenario A). In
contrast, if a group of individuals with PCa had lower
peak testosterone when they were young, their testos-
terone level will further decrease by the time of PCa
diagnosis. In this scenario, it is not surprising to ob-
serve a negative association between testosterone
levels and PCa if these patients are compared with the
controls whose dynamic change in testosterone levels
follow the pattern for most people in a population (See
Fig. 2- Scenario B). If all individuals from Scenario A
and Scenario B were analyzed together [25], no associ-
ation between testosterone levels and PCa is possible
(See Fig. 2- Scenario C).
The dynamic model and PCa racial disparities
Racial disparities in PCa are well documented [31–33]. In
the U.S., black males are approximately twice as likely to be
diagnosed with PCa compared to white males [34, 35].
However, the determinants of racial disparities in PCa re-
main unclear. Studies controlling for social impacts of PCa
have attempted to link testosterone levels to the racial dif-
ferences observed in PCa development [36–45], but find-
ings from these studies are inconsistent [36–46]. With the
dynamic model, the increased risk of PCa for blacks could
be due to more significant reductions in testosterone levels,
relative to that of whites. Evidence from previous studies in-
dicates that testosterone levels in black males declines
quicker with age when compared to white men. During
young adulthood, testosterone levels are higher in
blacks than in whites; but the difference diminishes with
age and completely disappears after the age of 60 years
of age [42, 47, 48]. Thus, the difference in the magni-
tude between young and older ages may explain, in part,
racial differences in PCa risk.
Fig. 1 A hypothetical model illustrates the role of age-related declines in testosterone (T) in thedevelopment of PCa
Fig. 2 Illustration of the change of testosterone throughout life rather than its level at older age which is implicated in the development of
prostate cancer (PCa). a. Illustration of a postive association between testosterone and PCa; b. Illustration of a negativeassociation between
testoterone and PCa; c. Illustration of no association between testoterone and PCa
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The dynamic model and risk factors for PCa
According to our dynamic model, any factor that affects
testosterone levels with age may play an etiological role
in the development of PCa. We applied the dynamic
model to explain the observed association between se-
lected known risk factors (physical activity, obesity, zinc
levels, and vitamin D levels) and PCa by focusing on the
ability of risk factors to mediate changes in testosterone
levels. This may occur either by slowing down or accel-
erating the process of the age-related declines in
testosterone.
Physical activity and risk of PCa Studies have shown
that both occupational and leisurely physical activity can
reduce the risk of PCa [49–53]. Many studies have also
found that physical activity can increase testosterone
levels, particularly among older men [54–57], contradic-
ting the current paradigm [58]. Our dynamic model
more fully allows for the idea that physical activity pre-
vents PCa by increasing testosterone levels, slowing
down the age-related declines in testosterone.
Obesity and risk of PCa Evidence from a meta-analysis
and systematic reviews suggest that obesity is linked
with an increased risk of PCa [59–61], yet explanations
for this relationship are weak. Based on our dynamic
model, we have at least two possible explanations for
this relationship: (1) Being overweight/obese accelerates
the age-related declines in testosterone, or (2) over-
weight/obesity is simply an indicator of accelerated tes-
tosterone declines [62]. Findings from epidemiological
studies indicate that compared to men with normal weight,
obese men have lower testosterone [63, 64]. However, the
underlying mechanisms are complex and include many fac-
tors such as inactive lifestyle, diet and accelerated testoster-
one metabolism. For example, studies found that adipose
tissue has a strong ability to convert androgen into estrogen
[65]. Moreover, the increased androgen-estrogen conver-
sion suppresses the release of luteinizing hormone, redu-
cing the production of testosterone by Leydig cells through
a negative hypothalamic-pituitary-gonadal axis feedback
loop [66, 67]. Thus, accelerating testosterone metabolism
through fat tissues could be one mechanism explaining the
mediating role of testosterone in the associations between
overweight/obesity and PCa. It is also possible that testos-
terone levels at baseline are associated with the develop-
ment of obesity; thus, a detailed time course evaluation of
testosterone may be required to fully understand the
relationship.
Zinc and risk of PCa Zinc is the most abundant trace
mineral in the body [68, 69], playing a pivotal role in im-
mune function, antioxidant activities, hormonal function
and cellular activities [70–72]. The prostate has the
highest concentration of zinc in the male body secreting
large amounts of the mineral into prostatic fluid [73].
Thus, there is a growing interest in investigating the role
of zinc in the carcinogenesis and pathogenesis of PCa
[74]. Many epidemiological studies have reported
marked decreases of zinc levels in PCa tissues versus
normal prostate tissues [75–83]. Furthermore, studies
suggest that high zinc levels are associated with antitumor
effects [84, 85]. Studies have shown that zinc is important
for testosterone production and zinc supplementation can
dramatically raise systemic testosterone levels [86–90].
While many biological pathways may be involved in the
protective effects of zinc against PCa, the inverse associ-
ation between zinc and PCa is consistent with the dy-
namic model we proposed. According to our model, the
protective effect of zinc on PCa could be through its role
in slowing down the age-related declines in testosterone.
Vitamin D deficiency and risk of PCa Research indi-
cates that exposure to UV radiation is inversely correlated
with PCa incidence and mortality [91–93] and that vitamin
D protects against prostate cancer [94–98]. Although the
underlying biological mechanisms between vitamin D and
PCa may be complex, our dynamic model provides an ex-
planation. Vitamin D may reduces PCa risk by slowing
down the age-related declines in testosterone. Studies have
shown that vitamin D can increase testosterone levels in
males [99–102]. In addition, vitamin D deficiency is more
prevalent among blacks than other racial groups [103, 104],
which may help explain more rapid testosterone declines
among blacks, and may also contribute to racial disparities
in PCa risk.
In summary, all the factors that are reported to be associ-
ated with PCa, as described above, are involved directly or
indirectly with levels of testosterone and changes with age.
The dynamic model, which proposes that the magnitude of
age-related declines in testosterone plays an essential role
in the genesis of PCa, may help explain the observed associ-
ations between these factors and risk of PCa. As the dy-
namic model suggests, a risk factor may be in the causal
pathway of PCa development through acceleration of age-
related declines in testosterone, while protective factors
may slow down the process. Observed relationships
between the risk/protective factors discussed above and tes-
tosterone are consistent with the dynamic model.
The dynamic model and the role of testosterone in PCa
growth
Different roles of testosterone in the onset and
progression of PCa To date, no documented epi-
demiological studies have distinguished testosterone as
a cause of PCa from a promotor of PCa growth. One
advantage of our dynamic model is that it can be used
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to assess the role of testosterone in the onset of PCa.
As the model suggests, the prostatic carcinogenesis may
be a process by which the normal prostate cells first adjust
themselves to progressive declining testosterone levels at
the cellular and receptor levels. As testosterone levels fall
below the threshold when normal prostate cells are not
able to make additional adjustments without mutations,
some of the normal prostate cells may evolve into cancer
cells. If additional testosterone is added before reaching
the threshold level, it may change the course of the dis-
ease. Among the mutated cancer cells, some of them
may become testosterone sensitive and increases in
testosterone may therefore promote these cancer cells
to grow. This notion is supported by evidence that cas-
tration (removal of endogenous testosterone) can in-
hibit PCa progression [6, 105], while administration of
exogenous testosterone can promote PCa progression
[106, 107]. Therefore, our dynamic model can also be
used to interpret the seemingly conflicted findings that
higher testosterone can prevent PCa onset but pro-
mote PCa progression after the disease occurs.
The dynamic model and androgen signaling pathway
Androgen receptor (AR) signaling plays an important
role in the normal development and homeostasis of the
prostate gland [108, 109]. AR is a nuclear receptor that
binds testosterone. The androgen-AR is directly involved
in a number of cellular processes that may lead to PCa
genesis, including the regulation of cell cycle, adhesion,
apoptosis and extracellular matrix remodeling and me-
tabolism [110]. According to our dynamic model, when
testosterone levels reach the threshold, all biochemical
processes that are involved with androgen-AR may be
altered. Moreover, the testosterone threshold for PCa of
an individual may also be determined by the total num-
ber and characteristics of AR in normal prostate cells
during young adulthood. The hypothesized threshold
could be higher for individuals with higher testosterone
than those with lower testosterone during young adult-
hood. Evidence from reported studies tends to support
this hypothesis. For example, evidence from randomized
controlled trials indicates that most prostate cancers that
initially responded to androgen deprivation therapy de-
velop into androgen-independent cancer after a few
years of treatment [111–114]. The mechanisms by which
tumor cells escape androgen ablation and become inde-
pendent of the need for androgen might not be to the
same as that of normal prostate cells turning into cancer
cells. However, they indicate that changes in testosterone
may lead to changes at the cellular and molecular levels.
Further investigation is needed to confirm these hypoth-
eses by mimicking testosterone decline with aging in
vivo or in vitro and studying its effects on changes in
prostate cells.
The dynamic model and testosterone replacement
therapy
The question whether testosterone replacement therapy is
a risk factor for PCa remains controversial [115]. If con-
firmed, our dynamic model suggests that testosterone re-
placement therapy should be provided before testosterone
levels drop below the threshold.
Some potential and practice-related questions that also
remain include dosage and timing for testosterone replace-
ment therapy to prevent PCa. According to our dynamic
model, the purpose of testosterone replacement therapy is
to compensate the age-related declines in testosterone and
to maintain testosterone levels above the threshold. In our
dynamic model, the concept of individual-based hypothe-
sized thresholds of testosterone provides a conceptual
framework supporting further research to determine the
protocol for individualized PCa prevention using exogenous
testosterone. Individual variation is important to under-
stand, as peak testosterone levels may influence threshold
levels, and some individuals may have stronger compensa-
tory function.
The timing for testosterone replacement therapy is also
important to consider. For primary prevention of PCa, tes-
tosterone replacement therapy needs to begin prior to the
onset of PCa, when testosterone levels are still above the
threshold. If some prostate cells have already become
cancer cells, administration of testosterone may promote
PCa growth. Given the challenges with determining indi-
vidual thresholds, longitudinal monitoring of testosterone
levels may be another approach to determining the appro-
priate dosage and timing of testosterone replacement
therapy. Examination of testosterone levels in the general
population may need to start before age 30 since the inci-
dence of PCa in autopsy studies has been reported to be
as high as 17 % in individuals less than 30 years old [116].
If possible, examination of testosterone levels in prostate
tissue may be more informative. When testosterone level
falls below a certain percent of the peak level of testos-
terone, testosterone replacement therapy can restore
testosterone levels. However, a recent clinical trial found
that intraprostatic testosterone and dihydrotestosterone
levels did not significantly increase after administration
of supraphysiologic doses of testosterone in patients
with symptomatic hypogonadism during the 6-months
of follow-up [117]. This finding suggests that the circu-
lating levels of testosterone may be less affected than
testosterone levels in the prostate. Nonetheless, the
intraprostatic levels of testosterone and dihydrotestos-
terone declined in the control group, suggesting that
treatment is working to increase the T and DHT levels.
Without treatment, those with symptomatic hypo-
gonadism may not have stable or slightly higher levels
of testosterone and dihydrotestosterone. Testosterone
replacement therapy has often been applied to treat
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male hypogonadism. Studies indicate that long-term tes-
tosterone replacement appears to be a safe and effective
for male hypogonadism [118–121]. Receiving long-term
testosterone replacement therapy for hypogonadism men
is not associated with an increased risk of PCa [122–124].
In addition, studies also found that men with benign pros-
tate biopsies do not have increased in prostate specific
antigen or a significantly increased risk of cancer com-
pared to normal men after one year of testosterone re-
placement therapy [125]. All findings suggest that
testosterone replacement therapy may not be harmful to
prostate health. Of course, it remains to be proven that
testosterone has any role in prostate carcinogenesis out-
side of causing growth of pre-existing PCa.
Summary
PCa is a killer of millions of men in the United States
and across the globe. The dynamic model provides a
novel conceptual framework to explain contradictory
findings from reported epidemiological studies. Our dy-
namic model suggests that a significant decline in tes-
tosterone levels with age may indicate the role of
testosterone in the development of PCa. Our theory
suggests a new direction for epidemiological studies to
examine the relationship between testosterone levels
and risk of PCa by targeting the magnitude of age-
related declines in testosterone rather than testosterone
levels measured at a single point in time. Some funda-
mental changes in study design are required. If the
model is confirmed, it will provide important insights in
the etiology and primary prevention of PCa.
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